The journal retracts the 26 February 2021 article cited above.
Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.
This retraction was approved by the Chief Editors of Frontiers in Endocrinology and the Chief Executive Editor of Frontiers. The authors have not responded to correspondence regarding this retraction.
Summary
Keywords
PTC, SHCBP1, cell stemness, EMT, integrin, Collagen
Citation
Frontiers Editorial Office (2024) Retraction: SHCBP1 promotes papillary thyroid carcinoma carcinogenesis and progression through promoting formation of integrin and collagen and maintaining cell stemness. Front. Endocrinol. 15:1379880. doi: 10.3389/fendo.2024.1379880
Received
31 January 2024
Accepted
31 January 2024
Published
13 February 2024
Approved by
Jeff M P Holly, University of Bristol, United Kingdom
Volume
15 - 2024
Updates
Copyright
© 2024 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.